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Abstract  
 
Background: Evolocumab, a fully human monoclonal antibody to PCSK9, markedly reduces 
LDL-C across diverse patient populations. The objective of this study was to assess the safety 
and tolerability of evolocumab in a pooled safety analysis from phase 2 or 3 randomized and 
placebo or comparator-controlled trials (integrated parent trials) and the first year of open-label 
extension (OLE) trials that included a standard-of-care control group. 
Methods: This analysis included adverse event (AE) data from 6026 patients in 12 phase 2 and 
3 parent trials, with a median exposure of 2.8 months, and of those patients, from 4465 patients 
who continued with a median follow-up of 11.1 months in two OLE trials. Adverse events were 
analyzed separately for the parent and OLE trials. Overall AE rates, serious AEs (SAEs), 
laboratory assessments, and AEs of interest were evaluated. 
Results: Overall AE rates were similar between evolocumab and control in the parent trials 
(51.1% vs 49.6%) and in Year 1 of OLE trials (70.0% vs 66.0%), as were those for SAEs. 
Elevations of serum transaminases, bilirubin and creatine kinase were infrequent and similar 
between groups. Muscle-related AEs were similar between evolocumab and control. 
Neurocognitive adverse events were infrequent and balanced during the double-blind parent 
studies (5 events [0.1%], evolocumab groups vs 6 events [0.3%], control groups). In the OLE 
trials, 27 patients (0.9%) in the evolocumab groups and 5 patients (0.3%) in the control groups 
reported neurocognitive AEs. No neutralizing anti-evolocumab antibodies were detected.  
Conclusions: Overall, this integrated safety analysis of 6026 patients pooled across phase 2/3 
trials and 4465 patients who continued in open-label extension trials for 1 year supports a 
favorable benefit-risk profile for evolocumab. 
Key Words: Adverse events, low density-lipoprotein cholesterol, monoclonal antibody, myalgia, 
PCSK9. 
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CLINICAL PERSPECTIVE   1 
What Is New? 2 
 Evolocumab was well tolerated in individual phase 3 studies.  3 
 This pooled analysis from the PROFICIO program, which included over 6000 patients 4 
from 12 phase 2 and 3 trials and the corresponding open-label extension trials, 5 
demonstrates that treatment with evolocumab for up to one year was not associated with 6 
discernible differences in adverse events, serious adverse events, or key laboratory 7 
assessments compared to control or standard of care.  8 
 In addition, adverse event rates did not increase among patients attaining very low levels 9 
of LDL-C (<25 mg/dL) compared to patients attaining LDL-C levels ≥40 mg/dL.  10 
What Are the Clinical Implications?  11 
 Evolocumab is approved for reducing serum levels of LDL-C across diverse patient 12 
populations.  13 
 The present analysis confirms that longer-term treatment with evolocumab, either alone 14 
or in combination with other lipid-lowering therapies, may have a favorable benefit-risk 15 
profile.  16 
17 
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INTRODUCTION   1 
Lowering LDL cholesterol (LDL-C) is an essential component of the therapeutic paradigm to 2 
reducing the morbidity and mortality associated with cardiovascular disease in both primary and 3 
secondary prevention settings. According to guidelines published around the world, statins are 4 
designated as first-line therapy for treating hypercholesterolemia, specifically in patients with 5 
high cardiovascular risk.1-4 However, a sizeable number of patients fail to achieve risk-stratified 6 
goal LDL-C levels or percent reductions with statin therapy alone5, 6 or in combination with 7 
ezetimibe.7 Blocking the interaction of proprotein convertase subtilisin/kexin type 9 (PCSK9) 8 
with LDL receptors (LDLR) has emerged as a highly effective therapeutic strategy for lowering 9 
LDL-C. Upon binding to LDLR, PCSK9 promotes increased lysosomal LDLR degradation, 10 
reduced hepatocyte cell surface expression of LDLR, and increased plasma LDL-C 11 
concentrations.8 12 
Evolocumab is a subcutaneously (SC)-administered fully human monoclonal IgG2 antibody to 13 
PCSK9 that is approved for use in the United States (US) and Europe, among other countries. 14 
Regulatory approval was based on review of the comprehensive clinical trial program, Program 15 
to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different 16 
Populations (PROFICIO). These trials demonstrated robust reductions of LDL-C with 17 
evolocumab treatment compared to placebo or ezetimibe across a broad population of patients 18 
with hypercholesterolemia, including those with familial hypercholesterolemia or other high-risk 19 
conditions, as well as statin-intolerant patients.9-18  20 
The safety of newly emerging anti-hypercholesterolemia agents is of paramount importance. 21 
Any such agent will be utilized on a chronic basis and must be both safe and well tolerated to 22 
promote optimal adherence. Each of the evolocumab trials showed a favorable safety and 23 
tolerability profile of evolocumab when compared to placebo or control regimens.9-18 24 
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To gain further understanding of the safety profile of evolocumab, as part of the PROFICIO 1 
program, we assessed safety and tolerability in a pooled analysis from patients enrolled in the 2 
randomized placebo- or ezetimibe-controlled phase 2 and 3 trials and during the Year 1 3 
standard-of-care (SoC)-controlled portion of the OLE trials. 4 
 5 
METHODS  6 
Patients 7 
Patients were enrolled in one of twelve phase 2 and 3 evolocumab parent clinical trials (Table 1 8 
and Figure 1).9-18 All patients provided written informed consent and the individual protocols 9 
were approved by each institutional review board. All patients completing a phase 2 or 3 parent 10 
trial on study drug were eligible to enroll in SoC-controlled open-label extension trials.  11 
Data Sources 12 
Each parent trial included was a double-blind, placebo-controlled randomized trial of 12 weeks’ 13 
duration with the exception of one trial of 6 weeks’ duration (THOMAS-1; NCT01849497) and 14 
one trial of 52 weeks’ duration (Durable Effect of PCSK9 Antibody Compared with Placebo 15 
Study [DESCARTES]).9 Dosing regimens and frequencies for evolocumab subcutaneous 16 
administration in the phase 2 parent trials were as follows: 70, 105, and 140 mg every 2 weeks 17 
(Q2W) and 280, 350, and 420 mg monthly (QM). The phase 3 parent trials utilized evolocumab 18 
regimens of 140 mg Q2W and/or 420 mg QM. Five trials included an ezetimibe-treated arm, 19 
alone or in combination with placebo.12, 13, 16-18 A total of 6026 patients were randomized and 20 
received at least 1 dose of evolocumab or control in the 12 phase 2 and 3 parent studies. Of 21 
these patients, 4465 (74%) enrolled in two ongoing open-label extension studies: Open-Label 22 
Study of Long-Term Evaluation Against LDL-C (OSLER)-1, which enrolled patients from the 23 
phase 2 trials,19 and OSLER-2, which enrolled patients from the phase 3 trials. The OSLER 24 
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trials included a standard-of-care (SOC)-controlled period for the first year of follow-up, followed 1 
by a period during which all patients received evolocumab. Upon enrollment to each OSLER 2 
trial, patients were re-randomized 2:1 to receive evolocumab plus SOC or SOC alone. 3 
Adverse event (AE) data were pooled from the 6026 patients in phase 2 and 3 studies 4 
(integrated parent studies) and from the 4465 patients after the SOC-controlled 1-year period in 5 
the OSLER studies. From these respective datasets, 5942 of 6026 patients and 4417 of 4465 6 
patients had at least 1 postbaseline LDL-C evaluation and were analyzed for safety associated 7 
with attainment of postbaseline on-treatment very low LDL-C (<25 mg/dL) in a post-hoc 8 
exploratory analysis. Data were compared between patients who never achieved LDL-C <40 9 
mg/dL and patients who ever achieved LDL-C <40 mg/dL. Patients in the latter category were 10 
further divided into subgroups of those who ever achieved LDL-C <25 mg/dL and patients who 11 
ever achieved LDL-C ≥25 mg/dL to <40 mg/dL. Data cut-off dates were October 1, 2014 for 12 
OSLER-1 and April 1, 2015 for OSLER-2; all patients from OSLER-1 had completed Year 1 by 13 
October 2014.   14 
Safety Endpoints 15 
Safety endpoints of the trials included the incidence of AEs, serious AEs, AEs of interest, 16 
laboratory values, and anti-evolocumab antibodies. Adverse events in this integrated analysis 17 
were coded using version 18.0 of the Medical Dictionary for Regulatory Activities (MedDRA).  18 
Adverse events in the individual parent trials were coded using the most current version of 19 
MedDRA at the time of database lock. Adverse events were graded according to the Common 20 
Terminology Criteria for Adverse Events (CTCAE) version 4.020 when applicable. The 21 
immunogenicity of evolocumab was evaluated using an electrochemiluminescent bridging 22 
immunoassay for the detection of binding anti-drug antibodies. For patients whose sera tested 23 
positive in the immunoassay, an in vitro biological assay was performed to detect neutralizing 24 
antibodies. 25 
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 1 
Statistical Analysis 2 
Safety analyses were conducted using descriptive statistics. Safety data were reported as 3 
observed. All analyses were performed with SAS/STAT, version 9.2 (SAS Institute, Cary, NC, 4 
USA). Patient incidences of AEs were summarized for all AEs, serious AEs, and AEs of interest. 5 
Adverse events were tabulated and reported separately for the parent studies and the OLE 6 
studies; an identical AE occurring in a patient in both the parent study and the OLE study was 7 
therefore recorded twice and reported separately as occurring in each dataset. Incidences of 8 
AEs were tabulated by system organ class, preferred term, and grade. Summaries of AEs 9 
occurring in at least 2% of the patients by preferred term in any treatment arm in parent or 10 
extension studies were provided in descending order of frequency. Descriptive statistics were 11 
provided for actual values and changes from baseline of laboratory parameters. Patient 12 
incidences of creatine kinase (CK) and liver function test abnormalities were summarized. The 13 
incidence of patients who developed anti-evolocumab antibodies at any time was tabulated. The 14 
studies were not powered for safety endpoints; therefore, no inferential statistical analyses with 15 
associated P values were conducted. 16 
 17 
RESULTS   18 
Baseline Characteristics 19 
The phase 2 and 3 parent evolocumab studies included in this analysis are summarized in 20 
Table 1. Trials included patients with primary hyperlipidemia, familial hypercholesterolemia, and 21 
statin intolerance. Comparator therapies included placebo and ezetimibe. Background therapies 22 
included no therapy, statin, or statin combined with ezetimibe (ezetimibe was not a comparator 23 
in these studies). Baseline characteristics of the integrated safety population are summarized in 24 
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Table 2. In the parent trial population, 49.5% of patients were men, 83.4% were white, the mean 1 
age of participants was 57.5 years, and 73.5% of patients were randomized to receive 2 
evolocumab in combination with a statin. In the extension trial population, 50.5% were men, 3 
85.7% were white, and the mean age of participants was 58.0 years. Of the 6026 patients 4 
enrolled in the parent studies, 4465 (74.1%) enrolled in the extension trials. Reasons for not 5 
continuing in the extension trials are detailed in Supplemental Table 1. Of the 1561 patients who 6 
did not enroll, 5.9% discontinued study drug early due to an adverse event in the parent trials. 7 
Median (range) evolocumab exposure was 2.8 (0-12.3) months in the parent studies and 11.1 8 
(0-13.1) months in the extension studies. Of the 6026 patients enrolled in the parent studies, 9 
4635 patients (76.9%) had ≥12 months of evolocumab exposure and 610 patients (10.1%) had 10 
≥18 months of evolocumab exposure. 11 
 12 
Safety Outcomes  13 
Overall AE rates were similar between evolocumab and control in the parent studies (51.1% vs 14 
49.6%, respectively) and in the Year 1 SoC-controlled period of the OLE studies (70.0% vs 15 
66.0%, respectively; Table 3). The majority of the difference between arms in the OLE studies is 16 
related to the occurrence of injection-site reactions (ISRs), which occurred in 4.4% of patients 17 
receiving evolocumab and are not reported for patients in the SoC-control arm, as these 18 
patients were not receiving injectable therapy. The majority of AEs were mild to moderate in 19 
severity in each treatment group. Serious AEs were also comparable between evolocumab and 20 
control, occurring in 2.8% and 2.1%, respectively, during the parent studies and in 7.8% and 21 
7.8%, respectively, during the OLE studies. Adverse events leading to study drug 22 
discontinuation in the parent trials occurred in 1.9% of evolocumab-treated patients and 2.3% of 23 
control-treated patients; 2.5% of evolocumab-treated patients discontinued drug due to an AE 24 
during the Year 1 SoC-controlled period of the OLE studies. Fatal adverse events occurred in 3 25 
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patients (0.08%) in the evolocumab arm and 1 patient (0.05%) in the control arm of the parent 1 
trials and in 4 patients (0.13%) in the evolocumab arm and 6 patients (0.40%) in the SoC arm of 2 
the OLE trials. Nasopharyngitis was the most common AE among evolocumab-treated patients 3 
during both periods (5.9% in the parent studies and 9.4% in the OLE studies; rates in the 4 
control- and SoC-treated groups were 4.8% and 9.5%, respectively). Injection-site reactions 5 
were observed in 3.3% of evolocumab-treated patients and 3.0% of control-treated patients in 6 
the parent trials. Among these patients, 95.4% of evolocumab-associated ISRs were mild in 7 
severity and 4.6% were of moderate severity. In the OLE trials, 91.6% of evolocumab-8 
associated ISRs were mild in severity and 8.4% were of moderate severity. Hypersensitivity 9 
reactions were observed in 3.2% of evolocumab-treated patients and 2.4% of patients in the 10 
control arm of parent trials and in 5.7% of evolocumab-treated patients and 4.3% of SoC-treated 11 
patients in the OLE trials. In the parent trials, 73.0% of evolocumab-associated hypersensitivity 12 
reactions were mild in severity, 26.2% were of moderate severity, and 1 patient (0.8%) 13 
experienced a severe reaction, consisting of worsening urticaria. In the OLE trials, the majority 14 
of hypersensitivity reactions were of mild to moderate severity.  15 
Muscle-related AEs (Table 4) were similar in overall frequency and type of event in the 16 
evolocumab, control, or SoC groups. Neurocognitive-related AEs (Table 5) were similar with 17 
evolocumab (0.1%) compared to control (0.3%) in the blinded phase 2 and 3 parent trials. In the 18 
OLE studies, the rate of neurocognitive events was 0.6%, and consisted primarily of amnesia 19 
and memory impairment in both treatment groups. Neurocognitive events were observed in 20 
0.9% of patients receiving evolocumab plus SoC and 0.3% of patients receiving SoC alone. 21 
There were small increases in amnesia (0.3% vs 0.1%) and in dementia, confusional state, and 22 
mental impairment (0.1% vs 0%). The proportion of patients discontinuing study drug for 23 
neurocognitive events was <0.1% in each arm of the parent trials and 0.1% of patients receiving 24 
evolocumab in the extension study.  25 
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Laboratory evaluations (Table 6) revealed that CK and liver enzyme elevations were infrequent 1 
and similar between groups. No drug-induced liver injury events were assessed to be 2 
associated with evolocumab use. No clinically meaningful changes in renal laboratory 3 
parameters occurred over 1 year in the extension studies or during the 52-week, randomized 4 
DESCARTES parent trial.  5 
No neutralizing anti-evolocumab antibodies were detected in the parent or OLE studies. The 6 
incidences of binding, non-neutralizing antibodies were 0.2% (9 of 3946 evolocumab-treated 7 
patients) during the parent studies and 0.4% (11 of 2976 evolocumab-treated patients) during 8 
the OLE. During the OLE, a total of 13 positive binding anti-evolocumab results were observed 9 
in the 11 patients. The majority (9 [69.2%]) of the positive results occurred at weeks 12 or 24. 10 
One positive result occurred at week 48, in a patient who had prior positive results at weeks 4 11 
and 12, and had received placebo during the parent trials. These data suggest that the 12 
development of binding, non-neutralizing anti-evolocumab antibodies does not increase with 13 
longer duration of evolocumab administration up to 48 weeks.  14 
No association between time exposure to evolocumab and AEs was observed (Table 7). Among 15 
the four quarters of the OLE, AE rates in evolocumab-treated patients ranged from 40.3% in the 16 
first quarter to 29.4% in the last quarter. Serious AE rates ranged from 2.2% in the first quarter 17 
to 1.8% in the last quarter. 18 
Mean changes from baseline for systolic and diastolic blood pressure were similar among 19 
treatment groups over time. In the integrated parent studies, the mean change from baseline to 20 
each study time point in systolic and diastolic blood pressure, respectively, ranged from -1.1 to 21 
0.6 mmHg (systolic) and -0.8 to 0.2 mmHg (diastolic) in the any evolocumab group and -1.0 to 22 
1.0 mmHg (systolic) and -0.8 to 0.1 mmHg (diastolic) in the any control group. In the Year 1 23 
SoC-controlled period, the mean change from baseline to each study time point in systolic and 24 
diastolic blood pressure, respectively, ranged from -0.9 to 2.1 mmHg (systolic) and -1.5 to 0.8 25 
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mmHg (diastolic) in the evolocumab plus SoC group and -0.4 to 2.0 mmHg (systolic) and 0.2 to 1 
0.9 mmHg (diastolic) in the SoC alone group. 2 
 3 
Safety Outcomes According to Lowest Achieved LDL-C (Nonrandomized Analysis)  4 
Baseline characteristics of patients according to the lowest level of LDL-C achieved (<25 mg/dL, 5 
≥25 mg/dL to <40 mg/dL, <40 mg/dL, or ≥40 mg/dL) are shown in Supplemental Table 2. 6 
Analysis of AEs according to these LDL-C subgroups demonstrated no evidence of increased 7 
risk associated with very low LDL levels achieved with evolocumab as monotherapy or in 8 
addition to background lipid-lowering therapy (Supplemental Table 3). In the parent trials, AE 9 
rates in patients receiving evolocumab who achieved LDL-C of <25 mg/dL or ≥25 mg/dL to <40 10 
mg/dL were 51.4% and 50.4%, respectively. These rates were similar to evolocumab-treated 11 
patients whose lowest LDL-C level was ≥40 mg/dL (52.1%). In the OLE trials, AE rates in 12 
patients receiving evolocumab who achieved LDL-C of <25 mg/dL or ≥25 mg/dL to <40 mg/dL 13 
were 70.2% and 69.2%, respectively. These rates were also consistent with evolocumab-treated 14 
patients whose lowest LDL-C level was ≥40 mg/dL (71.1%). No difference in neurocognitive or 15 
muscle-related AEs were observed in patients with progressively lower achieved LDL-C levels 16 
compared to patients with LDL-C ≥40 mg/dL. There were no discernible differences in key 17 
laboratory assessments with evolocumab compared to control or SoC across the lowest LDL-C 18 
levels achieved (Supplemental Table 4). 19 
DISCUSSION    20 
This pooled safety analysis from the evolocumab PROFICIO program demonstrates that the 21 
overall rates of AEs were similar in the evolocumab and control groups among over 6,000 22 
patients in randomized double-blind and OLE studies. Together with the robust LDL-C lowering 23 
observed with evolocumab compared to control across diverse patient populations in these 24 
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trials,9-18 these findings support a positive benefit-risk profile for evolocumab as an addition to 1 
the therapeutic armamentarium for LDL-C reduction and form the basis for regulatory approval 2 
of evolocumab. The favorable tolerability profile of evolocumab promotes adherence to 3 
treatment, and is thus reassuring given the fact that a sizeable number of patients treated with 4 
statins alone or in combination with ezetimibe are unable to achieve their risk-stratified goal for 5 
LDL-C reduction.7, 21 The majority of clinical trials in the PROFICIO program were designed to 6 
evaluate the addition of evolocumab to statin therapy with or without other lipid-lowering 7 
therapies to address this need. Therefore, the tolerability of evolocumab in the setting of 8 
polypharmacy in high-risk patients is of paramount importance.  9 
Evolocumab is a monoclonal antibody that binds PCSK9 in the extracellular space and induces 10 
steric hindrance so that PCSK9 is no longer able to bind to the LDLR and chaperone the 11 
receptor into the lysosome for proteolytic destruction.8, 22, 23 Due to their size, monoclonal 12 
antibodies are unlikely to undergo membrane transport into hepatocytes or other tissues. Due to 13 
their high target specificity and extracellular mechanism of action, monoclonal antibodies, like 14 
evolocumab, are unlikely to lead to AEs stemming from drug interactions.  15 
Myopathy, including rhabdomyolysis, is known to occur, albeit rarely, in patients receiving 16 
statins. This analysis explored the impact of evolocumab on risk for myositis, muscle fatigue, 17 
myalgia, elevation in serum levels of CK, and other muscle-related AEs. No evidence of 18 
increased risk for these events was observed, despite the inclusion of statin-intolerant patients 19 
who had experienced prior myalgia on statin treatment.  20 
Whether statin therapy is associated with an increased risk for neurocognitive deficits and 21 
dementia has been evaluated and no definitive evidence for the association exists.24 In both the 22 
Heart Protection Study (HPS) and the PROspective Study of Pravastatin in the Elderly at Risk 23 
(PROSPER) trials, subgroup analyses using neurocognitive testing failed to reveal any 24 
increased risk for neurocognitive disorders with statin therapy compared to placebo.25, 26 In the 25 
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integrated 12-week evolocumab parent studies, neurocognitive AEs were similar between 1 
evolocumab and control groups. In the open-label integrated extension studies, patients in this 2 
analysis were treated for up to 1 year, and neurocognitive AEs were numerically higher in the 3 
evolocumab plus SoC group (n=27 [0.9%]) relative to the SoC group (n=5 [0.3%]). The 4 
proportion of patients discontinuing study drug for neurocognitive events was low. Similar data 5 
were observed with alirocumab in the ODYSSEY LONG TERM study (1.2%, alirocumab vs 6 
0.5%, control).27 Certain limitations should be considered when interpreting these results. First, 7 
the numbers of neurocognitive events are small and are largely based on patient self-reporting. 8 
Investigators did not perform formal neurocognitive testing and data specific to neurocognitive 9 
events were not systematically collected. Second, the fact that the evolocumab extension 10 
studies were open label may have led to responder bias. Third, the length of follow-up is 11 
relatively short for identifying neurocognitive deficits. Finally, the population is relatively young 12 
(<4% of patients were 75 years of age or older at baseline) with a low rate (<10%) of 13 
cerebrovascular disease, suggesting a more favorable baseline neurocognitive status. There is 14 
no evidence that either evolocumab or evolocumab-PCSK9 complexes cross the blood-brain 15 
barrier to exert neurotoxicity,28 and preliminary data from 5777 participants did not support a link 16 
of a PCSK9 single-nucleotide polymorphism to cognitive dysfunction in PROSPER.29 We 17 
acknowledge that the neurocognitive safety of antihyperlipidemic agents is an important issue. A 18 
more definitive approach to evaluating the impact of evolocumab on neurocognitive function is 19 
underway. The Evaluating PCSK9 Binding antibody Influence oN coGnitive HeAlth in High 20 
cardiovascular Risk Subjects (EBBINGHAUS [NCT02207634]) trial is a dedicated study of 21 
cognition that enrolled over 1900 patients participating in the Further Cardiovascular Outcomes 22 
Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER; NCT01764633) trial, 23 
which in itself has enrolled 27,564 patients. In EBBINGHAUS, patients who were randomized to 24 
receive either evolocumab plus high- or moderate-intensity statin or placebo plus high- or 25 
moderate-intensity statin will be evaluated for prospective changes in neurocognitive function 26 
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using the Cambridge Neuropsychological Test Automated Battery (CANTAB). This study will 1 
provide a rigorous evaluation of the effects of evolocumab in combination with a statin on 2 
neurocognitive impairment compared with statin therapy alone. The effect of anti-PCSK9 3 
antibodies on cognitive function will also be monitored in ongoing phase 3 studies with other 4 
antibodies such as the alirocumab ODYSSEY OUTCOMES study.30 5 
No evidence emerged that evolocumab is associated with an increased risk for acute renal 6 
injury or renal failure and no impact on blood pressure was observed. No drug-induced liver 7 
injury events were assessed to be associated with evolocumab use in this analysis. No 8 
association between time exposure to evolocumab and AE rates were identified during the OLE. 9 
Finally, to date, neutralizing anti-evolocumab antibodies have not been detected.  10 
A post-hoc exploratory analysis according to achieved LDL-C levels revealed no evidence of 11 
differences in risk of AEs in patients achieving very low LDL-C levels (<25 mg/dL). This analysis 12 
is limited by the postbaseline definition of subgroups according to on-treatment LDL-C rather 13 
than randomized groups. As such, imbalances among groups can occur that can confound 14 
safety results. Additionally, small numbers of patients per subgroup precludes the ability to 15 
perform meaningful comparisons between evolocumab and control.  16 
 17 
CONCLUSIONS   18 
The PROFICIO integrated safety analysis of evolocumab included 6026 patients pooled across 19 
phase 2 and 3 trials and 4465 patients that continued in open-label extension trials. With 20 
median evolocumab exposures of 2.8 months (phase 2 and 3 trials) and 11.1 months (extension 21 
studies), the findings support a positive benefit-risk profile for evolocumab. Injection-site 22 
reactions associated with evolocumab were mild-moderate in severity. Evolocumab therapy was 23 
not associated with significant risk for hepatotoxicity, muscle-related AEs, or neurocognitive 24 
14 
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Figure Legends  1 
Figure 1 Title: Studies included in pooled analysis.  2 
Figure 1 Legend: Patients from 12 phase 2 and 3 studies and the 2 emanating open-label 3 
extension studies were included in the pooled analysis. *YUKAWA-2 was analyzed after 4 
integration for this analysis and was not included. AI/Pen, autoinjector pen; AMD, automated 5 
mini-doser; EZE, ezetimibe; HeFH, heterozygous familial hypercholesterolemia; OLE, open-6 
label extension; PBO, placebo; PFS, pre-filled syringe; Q2W, every two weeks; QM, monthly; 7 
SoC, standard of care 8 
 9 
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Table 1. Phase 2 and 3 Parent Evolocumab Studies 
Study Name N Trial Population and 
Baseline Fasting LDL-C 
Background 
Lipid Therapy 
Endpoint 
(Weeks) 
Dosing 
Phase 2 
LAPLACE-TIMI 
5710 
629 FH and NFH 
≥2.2 mmol/L (85 mg/dL)  
Statin 
(± ezetimibe) 
12  70, 105, 140 mg 
Q2W; 280, 350, 420 
mg QM 
RUTHERFORD14 167 HeFH 
≥2.6 mmol/L (100 mg/dL) 
 
Statin 
(± ezetimibe) 
12  350, 420 mg QM 
GAUSS18 157 Statin-intolerant 
(FH and NFH) 
≥2.6 mmol/L (100 mg/dL) 
Non-ezetimibe 
lipid-lowering 
therapy* 
12  280, 350, 420 mg QM 
MENDEL13 406 FH and NFH None 12  70, 105, 140 mg 
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≥2.6 mmol/L (100 mg/dL) Q2W; 280, 350, 420 
mg QM 
YUKAWA11 307 FH and NFH 
≥3.0 mmol/L (115 mg/dL) 
Statin 
(± ezetimibe) 
12  70 and 140 mg Q2W; 
280 and 420 mg QM 
Phase 3 
LAPLACE-216 1896 FH and NFH 
≥3.9 mmol/L (150 mg/dL) – 
no statin 
≥2.6 mmol/L (100 mg/dL) – 
nonintensive statin 
≥2.1 mmol/L (80 mg/dL) – 
intensive statin  
 Statins† 12 140 mg Q2W 
 
420 mg QM 
RUTHERFORD-215 329 HeFH  
≥2.6 mmol/L (100 mg/dL) 
Statin (± 
ezetimibe) 
12  140 mg Q2W 
420 mg QM 
25 
 
GAUSS-217 307 Intolerant to ≥2 statins 
FH and NFH 
≥ NCEP ATPIII LDL-C goal  
Non-ezetimibe 
lipid-lowering 
therapy* 
12 140 mg Q2W 
420 mg QM 
MENDEL-212 614 FH and NFH 
≥2.6 mmol/L (100 mg/dL) 
None 12 140 mg Q2W 
 
420 mg QM 
DESCARTES9 901 Various levels of CV risk 
FH and NFH 
≥1.9 mmol/L (75 mg/dL)  
Diet 
± atorvastatin 
± ezetimibe‡ 
52 420 mg QM 
THOMAS-1 
(NCT01849497) 
149 FH and NFH 
≥2.2 mmol/L (85 mg/dL) 
Statin (± 
ezetimibe) 
6 140 mg Q2W 
THOMAS-2 
(NCT01879319) 
164 FH and NFH 
≥2.2 mmol/L (85 mg/dL) 
Statin (± 
ezetimibe) 
Mean of 10 
and 12  
420 mg QM 
26 
 
*At screening, low or atypical dose statin permitted: weekly doses of ≤70 mg atorvastatin; ≤140 mg simvastatin, pravastatin, 
lovastatin; ≤35 mg rosuvastatin; ≤280 mg fluvastatin. 
†Patients randomized to 1 of 5 background statin doses: moderate intensity (atorvastatin 10 mg, simvastatin 40 mg, or 
rosuvastatin 5 mg daily) or high intensity (atorvastatin 80 mg or rosuvastatin 40 mg daily). 
‡Patients assigned background lipid-lowering therapy according to screening LDL-C and NCEP ATP III risk category: diet 
alone, diet plus atorvastatin 10 mg orally daily, diet plus atorvastatin 80 mg orally daily, or diet plus atorvastatin 80 mg orally 
daily and ezetimibe 10 mg orally daily. 
CV, cardiovascular; FH, familial hypercholesterolemia; HeFH, heterozygous familial hypercholesterolemia; NCEP ATPIII, 
National Cholesterol Education Program Adult Treatment Panel III; NFH, nonfamilial hypercholesterolemia; Q2W, every 2 
weeks; QM, monthly 
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Table 2. Baseline Characteristics 
  Integrated Parent Studies Integrated Interim Extension Studies  
  Control* Evolocumab SoC Evolocumab 
  (N=2080) (N=3946) (N=1489) (N=2976) 
Age, yr, mean (SD) 57.3 (11.1) 57.7 (11.3) 58.2 (10.9) 57.8 (11.0) 
Age group, n (%)     
<65 years 1494 (71.8) 2753 (69.8) 1020 (68.5) 2083 (70.0) 
 65 years 586 (28.2) 1193 (30.2) 469 (31.5) 893 (30.0) 
 75 years 65 (3.1) 158 (4.0) 62 (4.2) 111 (3.7) 
Male sex, n (%) 999 (48.0) 1983 (50.3) 765 (51.4) 1490 (50.1) 
Race or ethnicity, n (%)       
White 1754 (84.3) 3270 (82.9) 1267 (85.1) 2559 (86.0) 
Asian 184 (8.8) 355 (9.0) 123 (8.3) 231 (7.8) 
28 
 
Black 106 (5.1) 247 (6.3) 72 (4.8) 135 (4.5) 
Hispanic  122 (5.9) 202 (5.1) 70 (4.7) 145 (4.9) 
NCEP risk categories, n (%)       
High 640 (30.8) 1388 (35.2) 542 (36.4) 1038 (34.9) 
Moderately high 189 (9.1) 402 (10.2) 151 (10.1) 294 (9.9) 
Moderate 616 (29.6) 1157 (29.3) 428 (28.7) 878 (29.5) 
Lower 635 (30.5) 999 (25.3) 368 (24.7) 766 (25.7) 
Coronary artery disease, n (%) 350 (16.8) 791 (20.0) 307 (20.6) 589 (19.8) 
Cerebrovascular or peripheral 
arterial disease, n (%) 
153 (7.4) 356 (9.0) 141 (9.5) 266 (8.9) 
Randomized treatment 
assignment, n (%) 
  
  
Monotherapy  480 (23.1) 651 (16.5) N/A N/A 
Combination with statins 1466 (70.5) 2965 (75.1) N/A N/A 
29 
 
Statin intolerant† 134 (6.4) 330 (8.4) N/A N/A 
*Control includes placebo and ezetimibe treatment groups.  
†Inability to tolerate ≥1 statin at any dose or an increase in dose above weekly maximums of rosuvastatin, 35 mg; atorvastatin, 70 
mg; simvastatin, 140 mg; pravastatin, 140 mg; lovastatin, 140 mg; or fluvastatin, 280 mg, because of intolerable myalgia or myopathy 
(myalgia plus elevated creatine kinase) and having symptom improvement or resolution with statin discontinuation. 
N/A, not applicable (patients were randomized to evolocumab plus SoC or SoC alone); NCEP, National Cholesterol Education 
Program; SoC, standard of care 
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Table 3. Adverse Events 
  Integrated Parent Studies 
Integrated Interim Extension 
Studies  
Year 1 SoC-controlled Period 
  Control* Evolocumab SoC Evolocumab 
  (N=2080) (N=3946) (N=1489) (N=2976) 
Any AE, n (%) 1031 (49.6) 2016 (51.1) 982 (66.0) 2084 (70.0) 
Grade ≥2† 487 (23.4) 878 (22.3) 593 (39.8) 1211 (40.7) 
Grade ≥3† 66 (3.2) 147 (3.7) 125 (8.4) 253 (8.5) 
Grade ≥4† 6 (0.3) 24 (0.6) 12 (0.8) 23 (0.8) 
AEs occurring in >2% of patients in any treatment arm in parent or extension studies, n (%) 
Nasopharyngitis 99 (4.8) 231 (5.9) 142 (9.5) 281 (9.4) 
Upper respiratory tract 
infection 
56 (2.7) 127 (3.2) 74 (5.0) 162 (5.4) 
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Headache 66 (3.2) 120 (3.0) 32 (2.1) 107 (3.6) 
Back pain 57 (2.7) 117 (3.0) 55 (3.7) 126 (4.2) 
Myalgia 55 (2.6) 98 (2.5) 43 (2.9) 90 (3.0) 
Arthralgia 45 (2.2) 91 (2.3) 48 (3.2) 144 (4.8) 
Influenza 41 (2.0) 83 (2.1) 45 (3.0) 108 (3.6) 
Nausea 37 (1.8) 81 (2.1) 15 (1.0) 54 (1.8) 
Diarrhea 50 (2.4) 79 (2.0) 28 (1.9) 83 (2.8) 
Cough 26 (1.3) 78 (2.0) 49 (3.3) 106 (3.6) 
Pain in extremity 39 (1.9) 73 (1.8) 35 (2.4) 100 (3.4) 
Fatigue 40 (1.9) 71 (1.8) 15 (1.0) 85 (2.9) 
Muscle spasms 37 (1.8) 68 (1.7) 30 (2.0) 75 (2.5) 
Bronchitis 29 (1.4) 64 (1.6) 56 (3.8) 104 (3.5) 
Urinary tract infection 34 (1.6) 60 (1.5) 34 (2.3) 84 (2.8) 
Sinusitis 23 (1.1) 54 (1.4) 42 (2.8) 74 (2.5) 
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Hypertension 26 (1.3) 56 (1.4) 63 (4.2) 114 (3.8) 
Musculoskeletal pain 24 (1.2) 43 (1.1) 30 (2.0) 62 (2.1) 
Osteoarthritis 9 (0.4) 22 (0.6) 26 (1.7) 74 (2.5) 
Injection-site reactions‡, n (%) 63 (3.0) 131 (3.3) N/A 131 (4.4) 
Grade ≥2† 1 (<0.1) 6 (0.2) N/A 11 (0.4) 
Grade ≥3† 0 0 N/A 0 
Hypersensitivity reactions§, n (%) 50 (2.4) 126 (3.2) 64 (4.3) 170 (5.7) 
Grade ≥2† 16 (0.8) 34 (0.9)  23 (1.5) 69 (2.3) 
Grade ≥3† 0 1 (<0.1) 0 6 (0.2) 
Grade ≥4† 0 0 0 3 (0.1) 
Serious AEs, n (%) 43 (2.1) 110 (2.8) 116 (7.8) 231 (7.8) 
AEs leading to study drug 
discontinuation, n (%) 
48 (2.3) 75 (1.9) N/A 75 (2.5) 
Fatal adverse events, n (%) 1 (0.05) 3 (0.08) 6 (0.40) 4 (0.13) 
Adverse events are listed in decreasing order of frequency in the evolocumab arm of the parent trials.  
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*Control includes placebo and ezetimibe treatment groups.  
†Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade definitions are as follows: grade 1: mild; 
asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; grade 2: moderate; minimal, local 
or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living; grade 3: severe or medically 
significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care 
activities of daily living; grade 4: life-threatening consequences; urgent intervention indicated 20. 
‡Potential injection site reactions (ISR) were identified using preferred terms consistent with ISRs from the administration site 
reactions and ISRs high level terms. N/A indicates not applicable because these patients were receiving standard of care and 
therefore not receiving injections.  
§Potential hypersensitivity reactions were identified using the hypersensitivity standardized MedDRA query (SMQ). 
AE, adverse event; N/A, not applicable; SoC, standard of care. 
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Table 4. Muscle-related Adverse Events  
 
  Integrated Parent Studies 
Integrated Interim Extension 
Studies  
Year 1 SoC-controlled Period 
  Control* Evolocumab SoC Evolocumab 
  (N=2080) (N=3946) (N=1489) (N=2976) 
Any musculoskeletal and connective 
tissue disorder†, n (%)   
284 (13.7) 581 (14.7) 315 (21.2) 740 (24.9) 
Musculoskeletal and connective tissue 
disorders occurring in ≥1% in any arm, n 
(%) 
    
    Back pain 57 (2.7) 117 (3.0) 55 (3.7) 126 (4.2) 
    Myalgia 55 (2.6) 98 (2.5) 43 (2.9) 90 (3.0) 
    Arthralgia 45 (2.2) 91 (2.3) 48 (3.2) 144 (4.8) 
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    Pain in extremity 39 (1.9) 73 (1.8) 35 (2.4) 100 (3.4) 
    Muscle spasms 37 (1.8) 68 (1.7) 30 (2.0) 75 (2.5) 
    Musculoskeletal pain 24 (1.2) 43 (1.1) 30 (2.0) 62 (2.1) 
Osteoarthritis 9 (0.4) 22 (0.6) 26 (1.7) 74 (2.5) 
 Neck Pain 5 (0.2) 18 (0.5) 6 (0.4) 29 (1.0) 
Muscle-related adverse events are listed in decreasing order of frequency in the evolocumab arm of the parent trials.  
*Control includes placebo and ezetimibe treatment groups.  
†System organ class and preferred terms.  
AE, adverse event; SoC, standard of care. 
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 Table 5. Neurocognitive Adverse Events 
  Integrated Parent Studies 
Integrated Interim Extension 
Studies  
Year 1 SoC-controlled Period 
  Control* Evolocumab SoC Evolocumab 
  (N=2080) (N=3946) (N=1489) (N=2976) 
Any neurocognitive-related AE†, n (%) 6 (0.3) 5 (0.1) 5 (0.3) 27 (0.9) 
Amnesia 0 2 (0.1) 2 (0.1) 8 (0.3) 
Disorientation 2 (0.1) 1 (<0.1) 0 1 (<0.1) 
Memory impairment 1 (<0.1) 1 (<0.1) 3 (0.2) 7 (0.2) 
Delirium 0 1 (<0.1) 0 0 
Cognitive disorder 1 (<0.1) 0 0 1 (<0.1) 
Dementia with Lewy bodies 1 (<0.1) 0 0 0 
Disturbance in attention 1 (<0.1) 0 0 0 
Dementia 0 0 0 3 (0.1) 
Confusional state 0 0 0 2 (0.1) 
Mental impairment 0 0 0 2 (0.1) 
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Dementia Alzheimer's type 0 0 0 2 (0.1) 
Illusion 0 0 0 1 (<0.1) 
Transient global amnesia 0 0 0 1 (<0.1) 
Neurocognitive-related AEs leading to 
study drug discontinuation, n (%) 
1 (<0.1) 1 (<0.1) N/A 3 (0.1) 
Neurocognitive events are listed in decreasing order of frequency in the evolocumab arm of the parent trials.  
*Control includes placebo and ezetimibe treatment groups.  
†Neurocognitive events were identified using deliria (including confusion), cognitive and attention disorders and disturbances, 
dementia and amnestic conditions, disturbances in thinking and perception, and mental impairment disorders high-level group terms.  
AE, adverse event; N/A, not applicable; SoC, standard of care. 
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Table 6. Laboratory Investigations for Muscle Injury, Liver Function, and Renal Function  
  Integrated Parent Studies 
Integrated Interim Extension 
Studies  
Year 1 SoC-controlled Period 
  Control* Evolocumab SoC Evolocumab 
  (N=2080) (N=3946) (N=1489) (N=2976) 
CK     
Number of patients with any post-
baseline CK measurement 
2055 3892 1472 2962 
CK >5 x ULN, n (%) 14 (0.7) 27 (0.7) 17 (1.2) 17 (0.6) 
CK >10 x ULN, n (%) 5 (0.2) 9 (0.2) 9 (0.6) 7 (0.2) 
Liver function tests     
Number of patients with any post-
baseline liver function test measurement 
2055 3893 1477 2968 
ALT or AST >3 x ULN, n (%) 20 (1.0) 17 (0.4) 18 (1.2) 31 (1.0) 
ALT or AST >5 x ULN, n (%) 7 (0.3) 6 (0.2) 3 (0.2) 10 (0.3) 
Total bilirubin >2 x ULN, n (%) 3 (0.1) 6 (0.2) 2 (0.1) 8 (0.3) 
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(ALT or AST >3 x ULN) and (total 
bilirubin >2 x ULN), n (%) 
0 0 0 1 (<0.1) 
Renal function tests     
Serum creatinine     
Baseline mean (SD), μmol/L† 
80.2 (17.7) 
(n=302‡) 
80.0 (16.5) 
(n=599‡) 
80.6 (17.6) 80.4 (17.3) 
Number of patients evaluated at week 
52 
273 533 402 833 
Mean (SD) change from baseline at 
week 52, μmol/L† 
-0.8 (9.0) 0.8 (9.7) -0.7 (9.6) -0.8 (10.2) 
Blood urea nitrogen     
Baseline mean (SD), mmol/L§ 
5.6 (1.6) 
(n=302‡) 
5.6 (1.5) 
(n=599‡) 
5.8 (1.7) 5.8 (1.6) 
Number of patients evaluated at week 
52 
273 533 402 883 
Mean (SD) change from baseline at 
week 52, mmol/L§ 
0.04 (1.2) 0.06 (1.4) -0.01 (1.3) 0.09 (1.4) 
*Control includes placebo and ezetimibe treatment groups.  
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†Serum creatinine 88.4 μmol/L = 1 mg/dL 
‡For the parent trials, week 52 renal function data are available from the DESCARTES study, which enrolled 901 patients 
(evolocumab plus background therapy, n=599; placebo plus background therapy, n=302). 
§Blood urea nitrogen 0.36 mmol/L = 1 mg/dL 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; SoC, standard of care; ULN, upper limit of 
normal.  
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Table 7. Rates of Adverse Events in Evolocumab-treated Patients in the Open-label Extension Study by Treatment Period 
  Adverse Events in Evolocumab-Treated Patients 
Open Label Extension Study 
Period  
Months 
Evolocumab-treated Patients 
N 
Any Adverse Events 
N (%) 
Serious Adverse Events 
N (%) 
≥0 and <3 2976 1198 (40.3) 66 (2.2) 
≥3 and <6 2957 974 (32.9) 61 (2.1) 
≥6 and <9 2939 932 (31.7) 65 (2.2) 
≥9 and <12 2916 857 (29.4) 52 (1.8) 
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